{"doi":"10.1161/circulationaha.110.973735","title":"Dabigatran and Warfarin in Vitamin K Antagonist–Naive and –Experienced Cohorts With Atrial Fibrillation","abstract":"<jats:sec>\n            <jats:title>Background—</jats:title>\n            <jats:p>The comparison of anticoagulants dabigatran and warfarin might be most equitable in vitamin K antagonist (VKA)–naive patients.</jats:p>\n          </jats:sec>\n          <jats:sec>\n            <jats:title>Methods and Results—</jats:title>\n            <jats:p>\n              Warfarin and 2 doses of dabigatran—110 mg BID (D110) and 150 mg BID (D150)—were compared in a balanced population of VKA-naive (≤62 days of lifetime VKA exposure, with 33% never prescribed a VKA) and VKA-experienced patients with atrial fibrillation (n=18 113). For VKA-naive and -experienced patients assigned warfarin, the time in therapeutic range (international normalized ratio 2.0 to 3.0) was 62% and 67%, respectively, and 61% and 66% for those never and ever prescribed a VKA. In VKA-naive patients, stroke and systemic embolism rates were 1.57%, 1.07%, and 1.69% per year for D110, D150, and warfarin, respectively. D110 was similar to warfarin (\n              <jats:italic>P</jats:italic>\n              =0.65); D150 was superior (\n              <jats:italic>P</jats:italic>\n              =0.005). Major bleeding rates were 3.11%, 3.34%, and 3.57% per year, respectively. D110 and D150 were similar to warfarin (\n              <jats:italic>P</jats:italic>\n              =0.19 and\n              <jats:italic>P</jats:italic>\n              =0.55). Intracranial bleeding rates were 0.19%, 0.33%, and 0.73% per year, respectively. D110 and D150 were lower than warfarin (\n              <jats:italic>P</jats:italic>\n              &lt;0.001 and\n              <jats:italic>P</jats:italic>\n              =0.005). In VKA-experienced patients, stroke and systemic embolism rates were 1.51%, 1.15%, and 1.74% per year for D110, D150, and warfarin, respectively. D110 was similar to warfarin (\n              <jats:italic>P</jats:italic>\n              =0.32); D150 was superior (\n              <jats:italic>P</jats:italic>\n              =0.007). Major bleeding rates were 2.66%, 3.30%, and 3.57% per year, respectively. D110 was lower than warfarin (\n              <jats:italic>P</jats:italic>\n              =0.003); D150 was similar (\n              <jats:italic>P</jats:italic>\n              =0.41). Intracranial bleeding rates were 0.26%, 0.32%, and 0.79% per year, respectively. D110 and D150 were lower than warfarin (\n              <jats:italic>P</jats:italic>\n              &lt;0.001 for both). Results were similar for patients never on a VKA.\n            </jats:p>\n          </jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions—</jats:title>\n            <jats:p>Previous VKA exposure does not influence the benefits of dabigatran at either dose compared with warfarin.</jats:p>\n          </jats:sec>\n          <jats:sec>\n            <jats:title>Clinical Trial Registration—</jats:title>\n            <jats:p>\n              <jats:ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"http://www.clinicaltrials.gov\">http://www.clinicaltrials.gov</jats:ext-link>\n              . Unique identifier: NCT00262600.\n            </jats:p>\n          </jats:sec>","journal":"Circulation","year":2010,"id":605840,"datarank":0.7712495334753992,"base_score":5.14166355650266,"endowment":5.14166355650266,"self_citation_contribution":0.7712495334753992,"citation_network_contribution":0.0,"self_endowment_contribution":0.7712495334753992,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":170,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":29509,"name":"Lars Wallentin","orcid":"0000-0003-0378-6531","position":1,"is_corresponding":false},{"id":56134,"name":"Stuart J. Connolly","orcid":"0000-0002-7377-335X","position":2,"is_corresponding":false},{"id":56139,"name":"Amit Parekh","orcid":"0000-0002-7431-0760","position":3,"is_corresponding":false},{"id":1555004,"name":"Michael R. Chernick","orcid":null,"position":4,"is_corresponding":false},{"id":56140,"name":"Janice Pogue","orcid":null,"position":5,"is_corresponding":false},{"id":1555006,"name":"Timothy H. Aikens","orcid":null,"position":6,"is_corresponding":false},{"id":1267081,"name":"Sean Yang","orcid":null,"position":7,"is_corresponding":false},{"id":56141,"name":"Paul A. Reilly","orcid":null,"position":8,"is_corresponding":false},{"id":1554425,"name":"Gregory Y.H. Lip","orcid":null,"position":9,"is_corresponding":false},{"id":56136,"name":"Salim Yusuf","orcid":"0000-0003-4776-5601","position":10,"is_corresponding":false},{"id":56135,"name":"Michael D. Ezekowitz","orcid":"0000-0003-3623-2252","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-30T03:22:10.385899Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}